Maxigen Biotech Inc. (TPE:1783)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
46.75
-0.05 (-0.11%)
Jan 22, 2026, 1:35 PM CST
-9.75%
Market Cap3.78B
Revenue (ttm)792.49M
Net Income (ttm)234.07M
Shares Out80.69M
EPS (ttm)2.59
PE Ratio18.07
Forward PEn/a
Dividend0.83 (1.79%)
Ex-Dividend DateSep 5, 2025
Volume291,068
Average Volume128,894
Open46.85
Previous Close46.80
Day's Range46.30 - 47.10
52-Week Range35.55 - 55.00
Beta0.23
RSI66.61
Earnings DateMar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, and medical aesthetics, as well as engages in collagen purification activities. It also offers ophthalmic vis... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1783
Full Company Profile

Financial Performance

In 2024, Maxigen Biotech's revenue was 680.65 million, an increase of 9.41% compared to the previous year's 622.12 million. Earnings were 190.17 million, an increase of 14.68%.

Financial Statements